MIRUM PHARMACEUTICALS INC (MIRM) Stock News

Mirum Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025

Mirum Pharmaceuticals to Present Data at Upcoming Medical Congresses

FDA Approves Mirum Pharmaceuticals’ Drug For Rare Liver Disease Patients In Tablet Form: Retail Stays Bullish

Livmarli tablets will be available in June through Mirum Access Plus pharmacy.

Mentions: VTI IWM

Mirum’s LIVMARLI Now FDA Approved in Tablet Formulation

Earnings Scheduled For February 26, 2025

Mentions: CRH EYE MORN IONQ ...

Breaking Down Mirum Pharmaceuticals: 5 Analysts Share Their Views

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Is Verint Systems (VRNT) the Best Affordable Tech Stock to Buy According to Analysts?

We recently published a list of 12 Best Affordable Tech Stocks to Buy According to Analysts. In this article, we are going to take a look at where Verint Systems Inc. (NASDAQ:VRNT) stands against other best affordable tech stocks to buy according to analysts. Stock affordability can be assessed in multiple ways. The most common […]

Mentions: VRNT KRYS JPM INTC

LIVMARLI Now Approved in Japan for ALGS and PFIC

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update

Mirum’s CTEXLI™ (chenodiol) Tablets Receives FDA Approval for Treatment of Cerebrotendinous Xanthomatosis (CTX)

Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call on February 26, 2025

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum Pharmaceuticals Announces Preliminary Unaudited 2024 Net Product Sales and Cash Balance and Provides Corporate Updates

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum Pharmaceuticals to Showcase Data from its LIVMARLI and Volixibat Clinical Programs at AASLD’s The Liver Meeting

Mirum Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

Mirum Pharmaceuticals to Announce Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

Mirum Pharmaceuticals to Showcase LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Volixibat Granted Breakthrough Therapy Designation for Cholestatic Pruritus in Primary Biliary Cholangitis

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MIRM Stock Earnings: Mirum Pharmaceuticals Misses EPS, Beats Revenue for Q2 2024

MIRM stock results show that Mirum Pharmaceuticals missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.

Mirum Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update